Streetbeat News

Products Services

LLY

Eli Lilly has released an open letter clarifying that the company does not promote or encourage the use of Mounjaro (Tirzepatide) and Zepbound (Tirzepatide) outside of their FDA-approved indications. The letter emphasizes the company's commitment to patient safety and regulatory compliance.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:42 pm

FSR

Fisker Inc. is developing a dealer partnership model in North America and plans to implement a hybrid of direct sales and dealer arrangements in Europe. This strategy aims to expand its sales network and customer reach as it scales up operations.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:40 pm

LLY

Eli Lilly has launched LillyDirect, a digital healthcare platform for US patients with obesity, migraine, and diabetes. It provides disease management resources, access to healthcare providers, support, and home delivery of select Lilly medicines.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:39 pm

VRCA

Verrica Pharmaceuticals has received the minutes from a Type C meeting with the FDA concerning the clinical development of Ycanth, a treatment for common warts. The minutes will guide the company's next steps in the development and potential approval process.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:36 pm

CYBN

Cybin Inc. (NYSE:CYBN) reported positive Phase 2 results for its CYB003 deuterated psilocybin analog program for treating major depressive disorder (MDD), with a 79% remission rate at six weeks after two doses. The results show significant improvements over current SSRIs and other psychedelics, with plans to initiate a Phase 3 trial in early 2024. Cybin also plans to start a Phase 2 trial for CYB004 in generalized anxiety disorder (GAD) and has patents protecting its compounds until at least 2041.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:35 pm

CBUS

Cibus, a biotechnology company, has entered into a collaboration agreement with Interoc to provide an innovative weed control system for rice growers in Latin America. This partnership aims to enhance agricultural productivity and sustainability in the region.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:34 pm

ATAI

ATAI Life Sciences has made a strategic investment in Beckley Psytech to expedite the clinical development of short-duration psychedelics. This move aims to advance treatments in the mental health space, leveraging Beckley Psytech's focus on 5-MeO-DMT and other compounds for various psychiatric and neurological conditions.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:23 pm

WLDS

Wearable Devices has announced the release of the Mudra Developer Kit, an innovative technology for wristband neural gesture control. This technology allows users to control devices and interfaces with hand gestures by interpreting neural signals from the wrist.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:23 pm

CMND

SPRC

SciSparc and Clearmind Medicine have successfully collaborated throughout 2023 and are planning to enhance a variety of psychedelic-based treatments. Their joint efforts aim to innovate and improve therapeutic options in the field of psychedelic medicine.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:21 pm

KYMR

Kymera Therapeutics highlighted its immunology strategy and emerging pipeline of oral degraders targeting immuno-inflammatory diseases during its R&D Day. The company is advancing first-in-class oral degraders, including KT-621, KT-294, and KT-474 (SAR444656), which are expected to enter Phase 1 clinical trials in the second half of 2024 and first half of 2025, respectively. KT-474 is anticipated to complete enrollment in Phase 2 studies in Q4 2024, with results expected in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:15 pm